Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
I-Mab price target lowered to $35 from $80 at Piper Sandler » 16:14
05/27/22
05/27
16:14
05/27/22
16:14
IMAB

I-Mab

$8.28 /

-3.045 (-26.90%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on I-Mab to $35 from $80 and keeps an Overweight rating on the shares. While the analyst's investment thesis has not changed, he acknowledges that "biotech valuations have re-rated," and lowers the firm's price targets on companies in the coverage universe to "reflect this recent pullback and current market conditions."

ShowHide Related Items >><<
IMAB I-Mab
$8.28 /

-3.045 (-26.90%)

IMAB I-Mab
$8.28 /

-3.045 (-26.90%)

03/30/22 H.C. Wainwright
I-Mab price target lowered to $80 from $95 at H.C. Wainwright
03/29/22 Piper Sandler
I-Mab price target lowered to $80 from $90 at Piper Sandler
09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
IMAB I-Mab
$8.28 /

-3.045 (-26.90%)

IMAB I-Mab
$8.28 /

-3.045 (-26.90%)

Upgrade
Needham upgrades Boston Scientific to Buy, sees stock as potential M&A target » 07:46
05/27/22
05/27
07:46
05/27/22
07:46
BSX

Boston Scientific

$40.15 /

+0.07 (+0.17%)

, JNJ

Johnson & Johnson

$179.50 /

+0.2 (+0.11%)

Needham analyst Mike…

Needham analyst Mike Matson upgraded Boston Scientific (BSX) to Buy from Hold with a $48 price target. The company could likely sustain high single digit growth even assuming a moderate WATCHMAN slowdown as it has numerous new products across most of its businesses that could serve as an offset, the analyst tells investors in a research note. With Johnson & Johnson's (JNJ) M&A plans coming into focus as it spins off its consumer business, Boston Scientific could be its target and a "good fit", Matson adds.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

05/27/22 Needham
Boston Scientific upgraded to Buy from Hold at Needham
05/17/22 Citi
Boston Scientific price target lowered to $47 from $52 at Citi
05/16/22 Morgan Stanley
Boston Scientific named a 'Top Pick' at Morgan Stanley after meeting with CEO
05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

05/23/22 SVB Leerink
Johnson & Johnson assumed with an Outperform at SVB Leerink
05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
05/17/22 Citi
Johnson & Johnson price target lowered to $205 from $210 at Citi
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

JNJ Johnson & Johnson
$179.50 /

+0.2 (+0.11%)

BSX Boston Scientific
$40.15 /

+0.07 (+0.17%)

Thursday
Hot Stocks
Eli Lilly to present data on oncology portfolio » 18:21
05/26/22
05/26
18:21
05/26/22
18:21
LLY

Eli Lilly

$313.34 /

+6.24 (+2.03%)

Eli Lilly announced that…

Eli Lilly announced that data from its oncology portfolio will be presented at the 2022 ASCO Annual Meeting. The data include new analyses from studies of Verzenio - abemaciclib, a CDK4/6 inhibitor -, Retevmo - selpercatinib, a selective RET inhibitor -, and imlunestrant - an investigational, oral selective estrogen receptor degrader. Lilly will present analyses from the Verzenio Phase 3 monarchE study in high-risk HR+, HER2- early breast cancer assessing factors associated with increasing risk of treatment discontinuation, an update on the tumor agnostic efficacy of Retevmo in patients with RET fusion-positive solid tumors other than lung and thyroid cancer treated on the global, multicenter registrational LIBRETTO-001 trial, and updated monotherapy results from the ongoing, first-in-human, Phase 1 EMBER trial of imlunestrant in patients with estrogen receptor positive advanced breast cancer and endometrioid endometrial cancer.

ShowHide Related Items >><<
LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

05/23/22 SVB Leerink
Eli Lilly initiated with an Outperform at SVB Leerink
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Mizuho
Eli Lilly price target raised to $356 from $315 at Mizuho
04/29/22 Morgan Stanley
Eli Lilly price target raised to $369 from $364 at Morgan Stanley
LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

LLY Eli Lilly
$313.34 /

+6.24 (+2.03%)

Hot Stocks
4D pharma presents Phase 2 data of MRx0518 » 17:43
05/26/22
05/26
17:43
05/26/22
17:43
LBPS

4D pharma

$3.37 /

+0.09 (+2.74%)

, PFE

Pfizer

$53.99 /

+0.25 (+0.47%)

, MRK

Merck

$92.32 /

-1.465 (-1.56%)

4D pharma (LBPS)…

4D pharma (LBPS) announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with Bavencio - avelumab -, a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, at the 2022 ASCO Annual Meeting. Highlights from the trial in progress poster include: the multi-center study will enroll 30 patients with unresectable locally advanced or metastatic urothelial carcinoma. Patients will receive intravenous Bavencio - avelumab - every two weeks, in combination with one oral capsule of MRx0518 twice daily, until disease progression, patient withdrawal, or unacceptable toxicity. In addition to assessing the safety of the combination of MRx0518 with Bavencio, the study will assess the effect of the combination on progression-free survival at 6 months. The study is being conducted in collaboration with Merck (MRK), Darmstadt, Germany and Pfizer (PFE). Study sites are open for patient enrolment.

ShowHide Related Items >><<
PFE Pfizer
$53.99 /

+0.25 (+0.47%)

MRK Merck
$92.32 /

-1.465 (-1.56%)

LBPS 4D pharma
$3.37 /

+0.09 (+2.74%)

LBPS 4D pharma
$3.37 /

+0.09 (+2.74%)

03/24/22 Ladenburg
4D pharma price target raised to $37 from $35 at Ladenburg
07/09/21 Chardan
4D pharma assumed with a Buy at Chardan
PFE Pfizer
$53.99 /

+0.25 (+0.47%)

05/25/22 Piper Sandler
Piper Sandler says Ventyx Biosciences' VTX002 could produce superior efficacy
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
05/23/22 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
MRK Merck
$92.32 /

-1.465 (-1.56%)

04/12/22 Barclays
Merck price target raised to $97 from $94 at Barclays
04/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $15 from $40 at H.C. Wainwright
04/06/22 Morgan Stanley
Merck assumed with an Equal Weight at Morgan Stanley
04/05/22 BMO Capital
Merck targets 'ambitious' $10B revenue from cardiovascular franchise, says BMO
PFE Pfizer
$53.99 /

+0.25 (+0.47%)

MRK Merck
$92.32 /

-1.465 (-1.56%)

PFE Pfizer
$53.99 /

+0.25 (+0.47%)

MRK Merck
$92.32 /

-1.465 (-1.56%)

PFE Pfizer
$53.99 /

+0.25 (+0.47%)

MRK Merck
$92.32 /

-1.465 (-1.56%)

PFE Pfizer
$53.99 /

+0.25 (+0.47%)

MRK Merck
$92.32 /

-1.465 (-1.56%)

Hot Stocks
I-Mab reports safety and efficacy results from Phase 2 study of uliledlimab » 17:12
05/26/22
05/26
17:12
05/26/22
17:12
IMAB

I-Mab

$11.32 /

+0.68 (+6.39%)

I-Mab announced…

I-Mab announced preliminary data of its ongoing Phase 2 clinical trial with uliledlimab, a differentiated CD73 antibody, and its global clinical development plan. Preliminary results through December 2021 from an ongoing Phase 2 clinical study of uliledlimab in combination with toripalimab in patients with non-small cell lung cancer -NSCLC - were largely consistent with those observed in Phase 1 clinical trial in relation to favorable drug safety and pharmacokinetics and pharmacodynamic profile of ulilelimab. Uliledlimab appears safe and well-tolerated up to the highest doses tested, as a monotherapy and a combination therapy. Among three NSCLC patient cohorts who were under different treatment settings, clinical response varied. The highest response rates were observed in the patient cohort with advanced NSCLC who were previously ineligible for standard of care, while the other two cohorts with advanced NSCLC who were heavily treated showed a lower clinical response. The clinical response observed in this patient cohort displayed a correlation with CD73 expression in tumors. This Phase 2 clinical trial is still ongoing. The company plans to expand the study to focus on the selected NSCLC patient cohort. The future clinical development plan of uliledlimab includes a Phase 3 registrational clinical trial in patients with NSCLC to be expected next year if approved by the China National Medical Products Administration and another clinical trial in the U.S. in other selected cancer types and beyond combination with PD-1/PD-L1 therapy in the next 12 months.

ShowHide Related Items >><<
IMAB I-Mab
$11.32 /

+0.68 (+6.39%)

IMAB I-Mab
$11.32 /

+0.68 (+6.39%)

03/30/22 H.C. Wainwright
I-Mab price target lowered to $80 from $95 at H.C. Wainwright
03/29/22 Piper Sandler
I-Mab price target lowered to $80 from $90 at Piper Sandler
09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
IMAB I-Mab
$11.32 /

+0.68 (+6.39%)

IMAB I-Mab
$11.32 /

+0.68 (+6.39%)

Hot Stocks
Janssen granted orphan status for stem cell transplant conditioning » 12:02
05/26/22
05/26
12:02
05/26/22
12:02
JNJ

Johnson & Johnson

$179.05 /

-0.25 (-0.14%)

The FDA granted Johnson…

The FDA granted Johnson & Johnson's Janssen Research & Development orphan status for its treatment of patients undergoing myeloablative hematopoietic stem cell transplant conditioning to improve platelet recovery and reduce myeloablative bone marrow conditioning-related toxicities. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

05/23/22 SVB Leerink
Johnson & Johnson assumed with an Outperform at SVB Leerink
05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
05/17/22 Citi
Johnson & Johnson price target lowered to $205 from $210 at Citi
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

JNJ Johnson & Johnson
$179.05 /

-0.25 (-0.14%)

Hot Stocks
Sellas Life Sciences reports preliminary data from Phase 1/2 trial of GPS » 08:38
05/26/22
05/26
08:38
05/26/22
08:38
SLS

Sellas Life Sciences

$3.18 /

+0.1 (+3.25%)

, MRK

Merck

$93.79 /

-0.825 (-0.87%)

SELLAS Life Sciences…

SELLAS Life Sciences announced top-line clinical data from its Phase 1/2 trial of galinpepimut-S, the Company's Wilms Tumor-1-targeting peptide immunotherapeutic, in combination with Merck's anti-PD-1 therapy, KEYTRUDA(R) (pembrolizumab), in patients diagnosed with WT1 relapsed or refractory platinum resistant advanced metastatic ovarian cancer. Data from 15 patients enrolled in the study, conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., has been preliminarily analyzed with final data for all 17 patients enrolled in the clinical trial expected by the end of 2022. All enrolled patients were resistant to standard of care platinum-based therapy and 78.5 percent of evaluable patients were refractory to or had failed their first- or second-line therapies with 21.5 percent having failed three or more lines of therapy, including one patient who failed five previous lines of therapy. Of the 15 patients, 13 received at least three doses of GPS, the last of which was in combination with pembrolizumab, and were evaluable for response outcomes. Summary of Top-Line Clinical Data: The overall response rate of the trial is, similar to the response to checkpoint inhibitors. An ad hoc analysis of clinical outcomes in this cohort shows a disease control rate, the sum of overall response rate and rate of stable disease, of 53.9 percent at a median follow-up of 43.1 weeks. In a checkpoint inhibitor single agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2 percent, consistent with a DCR rate increase of 45 percent in the GPS combination with pembrolizumab over that seen for checkpoint inhibitors alone. Median progression-free survival was 12 weeks compared to 8.4 weeks for checkpoint inhibitors alone seen in studies with similar patient populations, a 43 percent increase in the GPS combination with pembrolizumab. Patients with fewer previous lines of chemotherapy experienced a more favorable median PFS than those with more than two previous lines: for patients with two or fewer previous lines of therapy treated with GPS in combination with pembrolizumab, median PFS was 24 weeks. With 43.1 weeks of follow-up the median overall survival has not been reached. The safety profile of GPS in combination with pembrolizumab was similar to pembrolizumab alone, with the only addition of low-grade rapidly resolving local reactions at the GPS injection site, consistent with observations from other GPS clinical studies.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$3.18 /

+0.1 (+3.25%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

SLS Sellas Life Sciences
$3.18 /

+0.1 (+3.25%)

04/07/22 Alliance Global Partners
Sellas Life Sciences price target lowered to $14 from $16.50 at Alliance Global Partners
12/03/21 Cantor Fitzgerald
Sellas Life Sciences price target lowered to $16 from $18 at Cantor Fitzgerald
07/21/21 Cantor Fitzgerald
Sellas Life Sciences initiated with an Overweight at Cantor Fitzgerald
07/21/21 Cantor Fitzgerald
Sellas Life Sciences initiated with an Overweight at Cantor Fitzgerald
MRK Merck
$93.79 /

-0.825 (-0.87%)

04/12/22 Barclays
Merck price target raised to $97 from $94 at Barclays
04/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $15 from $40 at H.C. Wainwright
04/06/22 Morgan Stanley
Merck assumed with an Equal Weight at Morgan Stanley
04/05/22 BMO Capital
Merck targets 'ambitious' $10B revenue from cardiovascular franchise, says BMO
MRK Merck
$93.79 /

-0.825 (-0.87%)

  • 01
    Apr
MRK Merck
$93.79 /

-0.825 (-0.87%)

SLS Sellas Life Sciences
$3.18 /

+0.1 (+3.25%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

Hot Stocks
Novocure enters clinical trial collaboration agreement with Merck » 08:05
05/26/22
05/26
08:05
05/26/22
08:05
NVCR

Novocure

$75.58 /

+1.98 (+2.69%)

, MRK

Merck

$93.79 /

-0.825 (-0.87%)

Novocure (NVCR) announced…

Novocure (NVCR) announced it has entered into a clinical trial collaboration agreement with Merck (MRK), to study the use of Tumor Treating Fields, or TTFields, concomitant with MSD's anti-PD-1 therapy Keytruda for the treatment of patients with newly diagnosed glioblastoma. This is the second clinical collaboration between Novocure and MSD.

ShowHide Related Items >><<
NVCR Novocure
$75.58 /

+1.98 (+2.69%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

NVCR Novocure
$75.58 /

+1.98 (+2.69%)

05/16/22 H.C. Wainwright
Novocure initiated with a Buy at H.C. Wainwright
05/13/22 Piper Sandler
Novocure price target lowered to $100 from $125 at Piper Sandler
02/07/22 Loop Capital
Loop starts Tumor Treating Fields 'pioneer' Novocure with a Buy
02/07/22 Loop Capital
Novocure initiated with a Buy at Loop Capital
MRK Merck
$93.79 /

-0.825 (-0.87%)

04/12/22 Barclays
Merck price target raised to $97 from $94 at Barclays
04/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $15 from $40 at H.C. Wainwright
04/06/22 Morgan Stanley
Merck assumed with an Equal Weight at Morgan Stanley
04/05/22 BMO Capital
Merck targets 'ambitious' $10B revenue from cardiovascular franchise, says BMO
NVCR Novocure
$75.58 /

+1.98 (+2.69%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

NVCR Novocure
$75.58 /

+1.98 (+2.69%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

MRK Merck
$93.79 /

-0.825 (-0.87%)

Wednesday
Hot Stocks
Eli Lilly to invest $2.1B in new manufacturing sites in Indiana » 13:17
05/25/22
05/25
13:17
05/25/22
13:17
LLY

Eli Lilly

$305.60 /

-0.58 (-0.19%)

Eli Lilly and Company…

Eli Lilly and Company announced plans to expand its manufacturing footprint in Indiana by investing $2.1B in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County. David Ricks, Lilly's chair and CEO, said, "These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers. We are pleased to be a founding investor at the LEAP Lebanon Innovation District." The investment in Boone County is contingent upon local zoning and annexation approvals, the company noted.

ShowHide Related Items >><<
LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

05/23/22 SVB Leerink
Eli Lilly initiated with an Outperform at SVB Leerink
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Mizuho
Eli Lilly price target raised to $356 from $315 at Mizuho
04/29/22 Morgan Stanley
Eli Lilly price target raised to $369 from $364 at Morgan Stanley
LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

LLY Eli Lilly
$305.60 /

-0.58 (-0.19%)

Tuesday
Hot Stocks
Janssen's treatment of PFPR, SFPR granted FDA orphan designation » 18:11
05/24/22
05/24
18:11
05/24/22
18:11
JNJ

Johnson & Johnson

$181.50 /

+2.03 (+1.13%)

According to a post on…

According to a post on the FDA's website, Janssen's treatment of primary failure of platelet recovery or secondary failure of platelet recovery in patients who have undergone allogeneic hematopoietic stem cell transplant, received FDA orphan designation. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

05/23/22 SVB Leerink
Johnson & Johnson assumed with an Outperform at SVB Leerink
05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
05/17/22 Citi
Johnson & Johnson price target lowered to $205 from $210 at Citi
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

JNJ Johnson & Johnson
$181.50 /

+2.03 (+1.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.